Chiesi Farmaceutici

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Retrieved on: 
Tuesday, August 8, 2023
Glioma, Niemann–Pick disease, Face, NDA, Janssen, G&A, Arimoclomol, Haemophilia B, Acquisition, Patient, NPC, Research, Environment, Pharmaceutical industry, Video game, Chiesi Farmaceutici

EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent operational achievements as XOMA accelerates its differentiated biotech royalty and milestone acquisition strategy.

Key Points: 
  • Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset
    EMERYVILLE, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its second quarter 2023 financial results and highlighted recent operational achievements as XOMA accelerates its differentiated biotech royalty and milestone acquisition strategy.
  • Our team has been sourcing and reviewing more royalty and milestone acquisition opportunities than ever,” said Brad Sitko, Chief Investment Officer of XOMA.
  • Other income, net was $0.6 million for the second quarter of 2023, compared to other income, net of $0.1 million in the corresponding quarter of 2022.
  • Net loss for the second quarter of 2023 was $5.4 million, compared to net loss of $4.7 million for the second quarter of 2022.

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Retrieved on: 
Monday, August 7, 2023
Protalix BioTherapeutics, Medsafe, European Medicines Agency, Tax, MD, Patient, European, Fabry disease, BLA, NYSE, Calendar, Gout, Half-life, Pharmacokinetics, Research, EMA, Russell, FIH, Growth, FDA, PEGylation, Biologics license application, Safety, Civil service commission, Health, Baylor University Medical Center, Israel Innovation Authority, FASN, Webcast, MAA, HDEC, European Commission, KOL, Clinical trial, EDT, Marketing, ERT, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry, Drug, Life insurance, Online shopping, EU, Fabry, Chiesi Farmaceutici

CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Key Points: 
  • "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer.
  • On May 5, 2023, the European Commission (EC) granted marketing authorization to Elfabrio (pegunigalsidase alfa) in the European Union.
  • On June 26, 2023, the Company was included in the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
  • Financial expenses, net were $0.8 million for the three months ended June 30, 2023, compared to financial income, net of $0.2 million for the three months ended June 30, 2022.

Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group

Retrieved on: 
Monday, July 31, 2023
Vamorolone, Marketing, LR, USD, EUR, Patient, FDA, Pharmaceutical industry, Chiesi Farmaceutici, Idebenone, LHON

53 LR

Key Points: 
  • 53 LR
    Santhera retains contingent value for LHON in U.S. and/or other indications worldwide
    Pratteln, Switzerland, July 31, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the full divestment of its Raxone®/idebenone business worldwide and for all indications to Chiesi Farmaceutici S.p.A., an international research focused healthcare group (Chiesi Group).
  • Under the terms of the agreement, Chiesi Group acquired all assets and certain liabilities related to idebenone in all indications worldwide, including Raxone in LHON, for which Chiesi already held exclusive license rights globally since 2019, except for North America and France.
  • The agreement simplifies the Raxone business significantly for both companies with Chiesi becoming the global brand owner while enabling Santhera to focus on the launch of vamorolone in Europe, subject to approval.
  • Chiesi Group also had the option to fully acquire said business outside North America.

Chiesi USA CEO Appointed to ASHP Foundation Board of Directors

Retrieved on: 
Thursday, July 20, 2023
Partnership, Education, Research, Pharmacy, ASHP, Pharmacist, Gold, Professional practice of behavior analysis, Health, Society, American Society of Health-System Pharmacists, Pharmaceutical industry, Nursing, Chiesi Farmaceutici

(key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Jon Zwinski, CEO and General Manager at Chiesi USA, has been appointed to the American Society of Health-System Pharmacists (ASHP) Foundation Board of Directors.

Key Points: 
  • (key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Jon Zwinski, CEO and General Manager at Chiesi USA, has been appointed to the American Society of Health-System Pharmacists (ASHP) Foundation Board of Directors.
  • “The ASHP Foundation is delighted to welcome Jon Zwinski to our Board of Directors,” said ASHP Foundation CEO Steven A. Rubloff.
  • Additionally, Chiesi sponsors the ASHP Foundation Pharmacy Leadership Scholars program.
  • Chiesi is also a Gold Level sponsor of the ASHP Corporate Partners Program, a collaboration between the ASHP Foundation, ASHP and corporations to promote improvements in patient care.

Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer

Retrieved on: 
Monday, July 17, 2023
Fulcrum, Acorda Therapeutics, University, Therapy, Cancer, MBA, Kellogg School, AMPS, Sutro Biopharma, Chiesi Farmaceutici, Metabolism, Civitas, Champaign–Urbana metropolitan area, Medicine, Drug discovery, Northwestern University, Ovation Pharmaceuticals, Management, Fine chemical

Mr. Stuart will succeed Jeff Goater, a venture partner at The Column Group, who has served as interim CEO of Atavistik Bio since January 2022 and will continue to serve as a Director on Atavistik Bio’s Board.

Key Points: 
  • Mr. Stuart will succeed Jeff Goater, a venture partner at The Column Group, who has served as interim CEO of Atavistik Bio since January 2022 and will continue to serve as a Director on Atavistik Bio’s Board.
  • “We are delighted to welcome Bryan as CEO to steer the exciting growth ahead for Atavistik Bio,” said Dr. John Josey, Atavistik Bio’s Board Chair.
  • “I’m proud of the remarkable progress that the Atavistik Bio team has made in such a short period,” said Mr. Goater.
  • I look forward to working with Bryan, the Atavistik Bio team, and my fellow Board members as the Atavistik Bio story continues to unfold.”

PODD Drug Delivery Conference Announces 2023 Keynotes and Agenda

Retrieved on: 
Wednesday, July 12, 2023
Teva Pharmaceuticals, Computational biology, GSK, Amgen, Gilead Sciences, Associate Director of National Intelligence and Chief Information Officer, Senior, Takeda, Administration, Chiesi Farmaceutici, Roche, Gene editing, Copley Place, Bristol Myers Squibb, Medicine, Research, MIT, Strategic Innovation Fund, Brain, CNS, AstraZeneca, PNS, AAV, Beam Therapeutics, Rare, Digital technology, Eli Lilly and Company, Novartis, Patient, AbbVie, Device, Novo Nordisk, Sanofi, Ionis Pharmaceuticals, Johnson & Johnson, Therapy, Conference, Takeda Pharmaceutical Company, Pharmaceutical industry, Medical device, Genentech, Pfizer

NEW YORK, July 12, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the 13th annual PODD: Partnership Opportunities in Drug Delivery conference will take place October 16-17 at the Westin Copley Place, in Boston, MA.

Key Points: 
  • The Conference Forum announced the 13th annual PODD Drug Delivery Conference's 2023 keynotes and plenary sessions.
  • NEW YORK, July 12, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the 13th annual PODD: Partnership Opportunities in Drug Delivery conference will take place October 16-17 at the Westin Copley Place, in Boston, MA.
  • "PODD is the most comprehensive industrial drug delivery partnering conference annually held in Boston," said Vincent Ling, Senior Director, Center for External Innovation at Takeda.
  • The PODD 2023 keynotes and featured speakers include:
    MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will discuss the state of innovation in the drug delivery industry.

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Retrieved on: 
Monday, July 10, 2023
Bispecific monoclonal antibody, Monoclonal antibody, Antigen, Bausch Health, Therapy, HER3, Critical, HER2, Neoplasm, Salix Pharmaceuticals, Biotechnology, Trastuzumab, Cancer, Daiichi Sankyo, Bystander effect, Rutgers University, US, Acquisition, Patient, EGFR, Minotaur, Epitope, Spacecraft, PD-1, Sanofi, IND, Metastasis, Vaccine, Pharmaceutical industry, Amgen, Pharmacy, Chiesi Farmaceutici, Hillstream loach, Willow

BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma (Nasdaq: HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients’ lives, today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment took into account, the pipeline’s near-term value creation opportunity and other factors. Hillstream will focus its pipeline on advancing novel oncology assets with the greatest potential and strong competitive profiles to address unmet needs across multiple solid tumors, such as bispecific antibodies and ADCs targeting novel conformational epitopes on high value validated targets, HER2 and HER3, with a more potent Bystander Effect.

Key Points: 
  • Bispecific antibodies (BsAbs) refer to a diverse group of molecules that recognize distinct epitopes on two different antigens, such as HER2 and HER3.
  • HER2, an extensively studied and validated target, has multiple approved therapeutics for solid tumors.
  • Hillstream’s lead asset, HSB-3215 is designed as a bispecific humanized immunoglobulin containing two arms targeting the extracellular domains of HER2 and HER3.
  • “I am thrilled to join Hillstream and look forward to working alongside the team as we further our development programs.

Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair

Retrieved on: 
Friday, July 7, 2023
Benefit corporation, Seed, Marketing, Creating shared value, Research, Sustainability, Patient, B Corporation (certification), Environment, Pharmaceutical industry, Management, Chiesi Farmaceutici

PARMA, Italy, July 7, 2023 /PRNewswire/ -- Chiesi announces the appointment of Alessandro Chiesi as Chair of the Group.

Key Points: 
  • PARMA, Italy, July 7, 2023 /PRNewswire/ -- Chiesi announces the appointment of Alessandro Chiesi as Chair of the Group.
  • Maria Paola Chiesi becomes Vice Chair.
  • Alessandro Chiesi was born in Parma 56 years ago, is married, and has 5 children.
  • "With great excitement, we entrust Alessandro and Maria Paola with the Presidency and Vice-Presidency of the Group today" - added Alberto Chiesi -.

Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair

Retrieved on: 
Friday, July 7, 2023
Benefit corporation, Seed, Marketing, Creating shared value, Research, Sustainability, Patient, B Corporation (certification), Environment, Pharmaceutical industry, Management, Chiesi Farmaceutici

PARMA, Italy, July 7, 2023 /PRNewswire/ -- Chiesi announces the appointment of Alessandro Chiesi as Chair of the Group.

Key Points: 
  • PARMA, Italy, July 7, 2023 /PRNewswire/ -- Chiesi announces the appointment of Alessandro Chiesi as Chair of the Group.
  • Maria Paola Chiesi becomes Vice Chair.
  • Alessandro Chiesi was born in Parma 56 years ago, is married, and has 5 children.
  • "With great excitement, we entrust Alessandro and Maria Paola with the Presidency and Vice-Presidency of the Group today" - added Alberto Chiesi -.

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Retrieved on: 
Friday, June 23, 2023
Florida Atlantic University, Senior, BS, Employment, Compensated emancipation, Finance, Atlantic University, Certified Public Accountant, Sale, Ernst & Young, PSO, Patient, SAN, Veloxis Pharmaceuticals, Ernst, Heron, Market for corporate control, Pleasure, Corporate finance, Growth, Therapy, Inducement, Accounting, Pharmaceutical industry, Chiesi Farmaceutici

SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs,  announced today the appointment of Ira Duarte as Chief Financial Officer.

Key Points: 
  • SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs,  announced today the appointment of Ira Duarte as Chief Financial Officer.
  • "I am excited to welcome Ira to Heron as Chief Financial Officer," said Craig Collard, Chief Executive Officer of Heron.
  • Ms. Duarte brings significant experience and expertise in financial leadership to Heron.
  • Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 – 2023, most recently as Chief Financial Officer, at Veloxis Pharmaceuticals, Inc., a fully integrated specialty pharmaceutical company.